Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Recruiting

Phase 2

Ruxolitinib vs. PrednisoneRuxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Code:

NCT06660355

Conditions

Chronic Graft-versus-host Disease (cGVHD)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ruxolitinib

Prednisone

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-09. This information was provided to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute on 2025-10-01.